VBL Therapeutics Terminates NASDAQ IPO Due To Shareholder Mishap

August 10, 2014 | VBL Therapeutics announced the termination of its underwriting agreement for its NASDAQ IPO by its underwriters Deutsche Bank and Wells Fargo Securities. According to Globe Newswire, the company was forced to terminate its IPO after an unnamed US shareholder did not fund payment shares it previously had agreed to purchase for the offering. As a result, no shares will be offered up in the IPO bid that went into effect on July 30, 2014. VBL Therapeutics is an Israeli clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases.